Olema Oncology to Participate in Upcoming Investor Conferences
November 06, 2024 07:01 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024 16:44 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
October 23, 2024 07:00 ET
|
Olema Oncology
OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission...
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 09, 2024 07:00 ET
|
Olema Oncology
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024 16:49 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024 07:00 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024 16:02 ET
|
Olema Oncology
Presented promising interim clinical results from the ongoing study of palazestrant in combination with ribociclib at the 2024 ESMO Breast Cancer Congress. Updated results expected to be presented at...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024 16:29 ET
|
Olema Oncology
SAN FRANCISCO, July 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...